USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba sky packaginng - baclofen (unii: h789n3fke8) (baclofen - unii:h789n3fke8) - baclofen 10 mg - baclofen tablets usp are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. patients should have reversible spasticity so that baclofen tablet treatment will aid in restoring residual function. baclofen tablets usp may also be of some value in patients with spinal cord injuries and other spinal cord diseases. baclofen tablets usp are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. the efficacy of baclofen tablets in stroke, cerebral palsy, and parkinson’s disease has not been established and, therefore, it is not recommended for these conditions. hypersensitivity to baclofen. safety and effectiveness in pediatric patients below the age of 12 years have not been established.

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba sky packaginng - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. - for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients hav

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba sky packaginng - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 25 mg - losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarction. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate tablets, usp are indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - benzonatate (unii: 5p4dhs6enr) (benzonatate - unii:5p4dhs6enr) - benzonatate usp is indicated for the symptomatic relief of cough. hypersensitivity to benzonatate or related compounds. pediatric use safety and effectiveness in children below the age of 10 have not been established. accidental ingestion resulting in death has been reported in children below age 10. keep out of reach of children.

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - hydralazine hydrochloride (unii: fd171b778y) (hydralazine - unii:26nak24ls8) - essential hypertension, alone or as an adjunct. hypersensitivity to hydralazine; coronary artery disease; mitral valvular rheumatic heart disease.

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - hydralazine hydrochloride (unii: fd171b778y) (hydralazine - unii:26nak24ls8) - essential hypertension, alone or as an adjunct. hypersensitivity to hydralazine; coronary artery disease; mitral valvular rheumatic heart disease.

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba sky packaginng - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam 250 mg - levetiracetam tablets are indicated for the treatment of partial-onset seizures in patients 1 month of age and older. levetiracetam tablets are indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. levetiracetam tablets are indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. levetiracetam tablets are contraindicated in patients with a hypersensitivity to levetiracetam. reactions have included anaphylaxis and angioedema [see warnings and precautions (5.4)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), including levetiracetam, during pregnancy. encourage women who are taking levetiracetam during pregnancy to enroll in the north american antiepileptic drug (naaed) pregnancy r

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba sky packaginng - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin tablets are indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, proteus vulgaris, providencia stuartii, morganella morganii, citrobacter freundii, pseudomonas aeruginosa, methicillin­susceptible staphylococcus aureus, methicillin-susceptible staphylococcus epidermidis, or streptococcus pyogenes. ciprofloxacin tablets are indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae, serratia marcescens , or pseudomonas aeruginosa. ciprofloxacin tablets are indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by escherichia coli, pseudomonas aeruginosa, proteus mirabilis, klebsiella pneumoniae, or bacteroides fragilis. ciprofloxacin tablets

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - metformin hydrochloride 850 mg - metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. metformin hydrochloride tablets and metformin hydrochloride extended-release tablets are contraindicated in patients with: -   severe renal impairment (egfr below 30 ml/min/1.73 m 2 ) [see warnings and precautions ( 5.1) ]. -   hypersensitivity to metformin. -   acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. risk summary limited data with metformin hydrochloride tablets or metformin hydrochloride extended-release tablets in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. published